16357-59-8 Usage
Description
N-Ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline, also known as 2-Ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline, is an organic compound with the chemical properties of a white to pale yellow solid. It is a versatile molecule that finds applications in various fields due to its unique structure and properties.
Uses
Used in Pharmaceutical Industry:
N-Ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline is used as a peptide condensing agent in the pharmaceutical industry for the synthesis of peptides. It is favored for its ability to cause little or no racemization during the process, ensuring the production of high-quality peptides with desired chirality.
Used in Chemical Synthesis:
In the field of chemical synthesis, N-Ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline serves as an amidation coupling reagent. Its role in this application is to facilitate the formation of amide bonds, which are crucial in the construction of various organic molecules and pharmaceutical compounds.
Used in Research and Development:
N-Ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline is also utilized in synthetic chemistry, discovery, and process research and development (R&D). Its unique properties make it a valuable tool for exploring new chemical reactions and developing innovative synthetic pathways.
Used in Membrane-bound Receptor Antagonism:
N-Ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline acts as an irreversible membrane-bound receptor antagonist. This application is particularly relevant in the study of cellular signaling and the development of new drugs targeting specific receptors.
Purification Methods
Dissolve EEDQ ~180g in CHCl3, evaporate to dryness in a vacuum. Add dry Et2O (20mL) and a white solid separates on standing. Set aside for a few hours, collect the solid, wash it thoroughly with cold Et2O and dry it in a vacuum (~140g, m 63.5-65o). A further crop of solid (~25g) is obtained from the filtrate on standing overnight. [Fieser & Fieser Reagents for Organic Synthesis 2 191 1969, Belleau et al. J Am Chem Soc 90 823 1968 and 90 1651 1968, Beilstein 21/3 V 28.]
Check Digit Verification of cas no
The CAS Registry Mumber 16357-59-8 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,6,3,5 and 7 respectively; the second part has 2 digits, 5 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 16357-59:
(7*1)+(6*6)+(5*3)+(4*5)+(3*7)+(2*5)+(1*9)=118
118 % 10 = 8
So 16357-59-8 is a valid CAS Registry Number.
InChI:InChI=1/C14H17NO3/c1-3-17-13-10-9-11-7-5-6-8-12(11)15(13)14(16)18-4-2/h5-10,13H,3-4H2,1-2H3/t13-/m1/s1
16357-59-8Relevant articles and documents
A highly enantioselective Mannich reaction of aldehydes with cyclic N-acyliminium ions by synergistic catalysis
Berti, Francesco,Malossi, Federico,Marchetti, Fabio,Pineschi, Mauro
supporting information, p. 13694 - 13697 (2015/09/01)
Matched combinations of Bronsted or Lewis acids with suitable pro-electrophiles and secondary amine organocatalysts enable the novel enantioselective syntheses of carbamoyl dihydroquinoline and tetrahydropyridine derivatives with concomitant formation of two stereocenters. A short formal asymmetric synthesis of (2R,2′R)-threo-methylphenidate (Ritalin) is also described.
Cyclic amino acid compounds pharmaceutical compositions comprising same and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
-
, (2008/06/13)
Disclosed are compounds which inhibit β-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits β-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.
Methods and compounds for inhibiting β-amyloid peptide release and/or its synthesis
-
, (2008/06/13)
Disclosed are compounds which inhibit β-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed pharmaceutical compositions comprising a compound which inhibits β-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.